Project Details
Description
A PHASE III, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL-GROUP, MULTICENTER, 52-WEEK EFFICACY AND SAFETY STUDY OF RO5285119 IN ADULTS WITH AUTISM SPECTRUM DISORDERS (ASD) WITH A 2-YEAR OPEN LABEL EXTENSION
| Status | Finished |
|---|---|
| Effective start/end date | 4/11/18 → 4/30/23 |
Funding
- HOFFMANN-LA ROCHE PHARMACEUTICALS
Fingerprint
Explore the research topics touched on by this project. These labels are generated based on the underlying awards/grants. Together they form a unique fingerprint.